☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
C4 Therapeutics
C4 Therapeutics and Merck KGaA Partner to Discover Protein Degraders Against Oncogenic Proteins
March 5, 2024
C4 Therapeutics Entered into an Exclusive License Agreement with Betta to Develop and Commercialize CFT8919 for Non-Small Cell Lun...
June 2, 2023
Load more...
Back to Home
Modal title
×
Modal body text goes here.